Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Pediatric Brain Tumor 1Pancreatic Neoplasms 1Neoplasms 1Mesothelioma 1Melanoma 1Glioma 1Glioblastoma 1Colonic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 5Temozolomide 2Immunotherapy, Adoptive 2Aminolevulinic Acid 2thymoglobulin 1temsirolimus 1poly ICLC 1pembrolizumab 1pazopanib 1orludodstat 1keyhole-limpet hemocyanin 1gallium Ga 68 dotatate 1fludarabine phosphate 1fluciclovine F-18 1dexamethasone acetate 1dexamethasone 21-phosphate 1cixutumumab 1carbon-11 acetate 1cabazitaxel 1bicalutamide 1azeliragon 1auricularum 1atezolizumab 1abemaciclib 1Valproic Acid 1Trail Making Test 1Topotecan 1Thiotepa 1Tacrolimus 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Glioma × poly ICLC × Clear all
NCT02754362 2020-01-13

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

NYU Langone Health

Phase 2 Withdrawn
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡